Karkeet RM, Zekri AN, Sayed-Ahmed MM, Sherif GM, et al. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial. PLoS One 2022;17:e0278282.
PMID: 36480560